News

Impilo believes in transparency. We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Accordingly, we present information about our operations and our investments in order to increase transparency.  

29 Apr 2020

PharmaMar signs an agreement with Immedica

PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and some Middle Eastern countries

19 Nov 2019

The Swedish Financial Supervisory Authority has approved the consortium of investors arranged by Impilo as new owners of Euro Accident Livförsäkring

01 Oct 2019

Immedica acquires the rights for Ophthalmology products for European countries

Immedica Pharma AB (Immedica) has acquired rights to four ophthalmology products involving indications for the treatment of glaucoma, allergic conjunctivitis, and inflammatory conditions of the eye, in certain European countries from Novartis. The deal encompasses commercial and distribution rights and intellectual property for the four products in the territories.

17 Sep 2019

Impilo launches collaboration with Kenyan non-profit innovators

The Nordic investment company Impilo partners with Lwala Community Alliance in Kenya to reduce maternal and child mortality in rural areas. Impilo will provide both financial and strategic support to scale their innovative community-based model.

03 Sep 2019

A consortium of investors arranged by Impilo has entered an agreement to acquire Euro Accident Livförsäkring from National General Holdings Corp.

Euro Accident is a leading Swedish specialist in health-related insurance and employee wellbeing, active primarily within the long-term disability, pension risk and private health insurance. Impilo together with management and a group of other investors have agreed to acquire Euro Accident from the current owners National General Holdings Corp., a specialty personal lines insurance company listed on NASDAQ (NGHC).

11 Jul 2019

The Fertility Partnership acquires VivaNeo to create Northern Europe’s leading Fertility Group

The Fertility Partnership has today signed an agreement to acquire VivaNeo GmbH from Waterland Private Equity. VivaNeo is one of the leading European providers of fertility services with 9 clinics supported by 5 satellite clinics across Germany, Austria, Denmark and the Netherlands. The group includes a blood diagnostics laboratory in Germany servicing the local market and some international clinics, as well as a dialysis business in Germany.

22 Mar 2019

Impilo acquires The Fertility Partnership, a leading European IVF platform

Impilo has today signed an agreement to acquire a majority holding in The Fertility Partnership (“TFP”), one of the leading European providers of fertility services, ultrasound pregnancy scans and hormone treatments with activities in the UK and Poland. The group comprises 8 IVF clinics in the UK, which in turn are supported by a network of 27 satellites, thus enabling local patient care; 2 IVF clinics in Poland, the leading independent provider of ultrasound services through a network of 88 ultrasound across the UK; and a nascent hormone treatment business.

07 Mar 2019

Impilo increases its ownership in Humana and becomes the largest shareholder

Impilo increases its shareholding in Swedish care company Humana AB (publ) (”Humana”), through the acquisition of approximately 6 percent of the shares outstanding from Argan Capital. Through this investment, Impilo becomes the largest shareholder in Humana with a total shareholding of 18.5 percent of the shares outstanding.

14 Jan 2019

Impilo becomes second largest shareholder in Humana

STOCKHOLM, January 14 2019 – Today, Impilo announces that it has entered into an agreement to acquire the equivalent of 12.5 percent of the shares in Swedish care company Humana AB (publ) (”Humana”) from Humana’s largest shareholder, Argan Capital. Through this investment, Impilo becomes the second largest shareholder in Humana and intends to contribute actively in the continued development of the company. Humana was founded in 2001 and is a leading provider of care services in the Nordic region, currently with c. 15,000 employees and a turnover of SEK 6.6bn. The company serves about 8,000 clients in Sweden, Norway, Finland and Denmark.

29 Dec 2018

Immedica acquires the rights for Ravicti® and Ammonaps® outside North America and Japan

Today, through its entity Medical Need Europe AB, Immedica has acquired rights for the products Ammonaps® and Ravicti®, indicated for the treatment of Urea Cycle Disorders (UCD), in all territories outside North America and Japan from Horizon Pharma plc (NASDAQ: HZNP) (Horizon). The deal encompasses all IP and commercial and distribution rights for the two products in the territories. Horizon will retain rights for the products in North America and Japan. More information is available at www.immedica.com or www.medicalneed.com

See more news

Media

We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Here you will find press information, news and media material.

Go to Cision

Redefining know-how

Impilo is zulu and xhosa meaning life, health or simply the meaning of a healthy life. We chose this name to highlight our sector-focus and our ambition to provide know-how and new perspectives to Nordic healthcare companies.